bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
pharma · Rheumatoid Arthritis · Multiple Myeloma
Centocor
Centocor B.V.
Centocor drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Malvern, USA HQ
1979 Founded
568 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Malvern, USA
- Founded
- 1979
- Employees
- 568
- Programs
- 2
- Drugs
- 4
- Patents
- 1
Centocor pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Centocor drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Centocor in public FDA and regional records.
-
Development asset linked to Centocor in public FDA and regional records.